Every material Form 8-K IMPACT BIOMEDICAL INC. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Impact Biomedical announced that the SEC declared effective on October 23, 2026, the Form F-4 registration statement for its proposed business combination with Zoar Limited. Impact stockholders will vote on the merger at a special meeting on November 13, 2026, and closing remains subject to that vote and NYSE American listing approval. The filing does not include financial results, so the effect on shareholder value cannot be assessed from it.
SEC declared the Form F-4 effective on October 23, 2026; proxy materials mailed the same day
Special stockholder meeting scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time
Combined company expected to trade on NYSE American as ZOAR, subject to listing approval
Company states there can be no assurance the business combination will be completed on any particular timetable or at all
Impact Biomedical said a Form F-4 registration statement for its proposed merger with Zoar Limited was filed with the SEC on September 10, 2026, and announced it on September 16, 2026. The filing is a step toward closing, which remains subject to SEC effectiveness, Impact stockholder approval, and NYSE American approval of the listing of PubCo shares.
Form F-4 registration statement filed with the SEC on Thursday, September 10, 2026, by Zoar Limited (PubCo)
Closing is subject to SEC effectiveness, Impact stockholder approval, and NYSE American listing approval
Combined company expected to be a pharmaceutical company focused on Active Pharmaceutical Ingredients and intermediates
Impact Biomedical Inc. (NYSE American: IBO) said its 1-for-12.62 reverse stock split will take effect at 12:01 a.m. Eastern Time on September 23, 2026, reducing outstanding common shares from about 107.8 million to about 8.5 million. The company said the split is connected to its proposed merger with Zoar Limited and to regaining compliance with NYSE American listing requirements, but it gave no assurance that either goal will be met. The filing also corrects an earlier press release that misstated the merger exchange ratio.
Reverse split ratio of 1-for-12.62 takes effect 12:01 a.m. Eastern Time on September 23, 2026; ticker remains IBO under a new CUSIP.
Shares outstanding expected to fall from 107,821,231 to 8,543,679, subject to rounding; fractional shares are rounded up to the next whole share.
Merger terms: one Zoar Limited share for each Impact share held immediately before the merger, after giving effect to the split.
A corrected press release replaces the September 11, 2026 release, which incorrectly stated a one-for-four exchange ratio.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IMPACT BIOMEDICAL INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →